Synergistic bacterial compositions and methods of production and use thereof
Provided are therapeutic compositions containing Ecobiotic™ populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.
1. A composition comprising a first species of isolated bacterium, a second species of isolated bacterium, and a capsule; wherein the first species is Clostridium symbiosum and the second species is Clostridium orbiscindens ; wherein the Clostridium orbiscindens comprises a 16S rDNA sequence that is at least 97% identical to SEQ ID NO: 548, wherein the first species and the second species are capable of inhibiting Clostridium difficile ( C. difficile ) growth as measured by a CivSim assay; and wherein the capsule encapsulates the first species and the second species.
2. The composition of claim 1 , wherein the first species and the second species are capable of inhibiting C. difficile growth in the CivSim assay with a confidence interval of >99% (+++).
3. The composition of claim 1 , wherein the first species, the second species, or both are in the form of spores.
4. The composition of claim 1 , which is formulated for populating the gastrointestinal tract of the subject.
5. The composition of claim 1 , wherein the first species, the second species, or both are lyophilized.
6. A single dose unit comprising a first species of isolated bacterium, and a second species of isolated bacterium, and a capsule; wherein the first species and the second species are capable of inhibiting Clostridium difficile ( C. difficile ) growth as measured by a CivSim assay and/or populating the gastrointestinal tract of a subject; wherein the first species is Clostridium symbiosum and the second species is Clostridium orbiscindens ; wherein the Clostridium orbiscindens comprises a 16S rDNA sequence that is at least 97% identical to SEQ ID NO: 548, and wherein the capsule encapsulates the first species and the second species.
7. A kit comprising in one or more containers the composition of claim 1 .
8. A pharmaceutical formulation comprising the composition of claim 1 .
9. The pharmaceutical formulation of claim 8 , further comprising an additional agent.
10. A method of producing a bacterial composition, comprising combining a first species of isolated bacterium and a second species of isolated bacterium, wherein the first species is Clostridium symbiosum and the second species is Clostridium orbiscindens , wherein the Clostridium orbiscindens comprises a 16S rDNA sequence that is at least 97% identical to SEQ ID NO: 548, and wherein the first species and the second species are capable of inhibiting Clostridium difficile ( C. difficile ) growth and/or populating the gastrointestinal tract of a subject.
11. The method of claim 10 , wherein the first species and the second species are lyophilized.
12. The composition of claim 1 , wherein the Clostridium orbiscindens comprises a 16S rDNA sequence that is at least 98% identical to SEQ ID NO: 548.
13. The composition of claim 1 , wherein the Clostridium orbiscindens comprises a 16S rDNA sequence that is at least 99% identical to SEQ ID NO: 548.
14. The composition of claim 1 , wherein the Clostridium orbiscindens comprises the 16S rDNA sequence set forth in SEQ ID NO: 548.
15. The single dose unit of claim 6 , wherein the Clostridium orbiscindens comprises a 16S rDNA sequence that is at least 98% identical to SEQ ID NO: 548.
16. The single dose unit of claim 6 , wherein the Clostridium orbiscindens comprises a 16S rDNA sequence that is at least 99% identical to SEQ ID NO: 548.
17. The single dose unit of claim 6 , wherein the Clostridium orbiscindens comprises the 16S rDNA sequence set forth in SEQ ID NO: 548.
18. The method of claim 10 , wherein the Clostridium orbiscindens comprises a 16S rDNA sequence that is at least 98% identical to SEQ ID NO: 548.
19. The method of claim 10 , wherein the Clostridium orbiscindens comprises a 16S rDNA sequence that is at least 99% identical to SEQ ID NO: 548.
20. The method of claim 10 , wherein the Clostridium orbiscindens comprises the 16S rDNA sequence set forth in SEQ ID NO: 548.